Instinct Bio Technical Company Holdings Inc. BIOT
Company Overview
Instinct Bio Technical Company Holdings Inc. focuses on stem cell and regenerative medicine-related products, wellness, and beauty encompassing from research and development, manufacturing, branding, and distribution. It has a strategic collaboration with PT Parva Candela to develop cosmetics business in Indonesia. The company was founded in 2011 and is headquartered in Tokyo, Japan.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Nov 2024 Revenue of $2.76M (-19.6% YoY); net profit $74.66K.
- Trailing 12 Months Year-on-year growth — revenue -19.6%, earnings -86.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -19.6%, profit CAGR -86.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -19.58% |
| 1 Year: | -19.58% |
Compounded Profit Growth
| 5 Years: | -86.30% |
| 1 Year: | -86.30% |
Stock Price Performance
| 1 Year: | -97.51% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -3.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)0.32 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -19.6% CAGR over 5 years.
- Earnings shrank at -86.3% CAGR over 5 years.
- Trading 97.5% below its 52-week high.
- RSI at 0 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BIOT Instinct Bio Technical Company Holdings Inc. | 0.39 | -39.00 | $11.23M | 0.00% | 5.32% | 3.19% | -19.58% | -86.30% |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 38.82 | $850.02B | 0.93% | 16.83% | 22.31% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 910.18 | 45.88 | $403.65B | 0.65% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.36 | 26.53 | $380.17B | 2.41% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 145.58 | 21.99 | $338.39B | 2.95% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 184.73 | 25.37 | $287.92B | 3.09% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 138.45 | 18.15 | $189.12B | 4.43% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 79.73 | 17.18 | $139.30B | 1.69% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | BTI British American Tobacco p.l.c. | 55.15 | 14.18 | $118.73B | 5.98% | 12.44% | 13.42% | -2.53% | 5.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Nov 2023 | Nov 2024 |
|---|---|---|
| Revenue | 3.43M | 2.76M |
| Cost of Revenue | 456.05K | 761.92K |
| Gross Profit | 2.98M | 2.00M |
| Operating Expenses | 2.58M | 2.07M |
| Operating Income | 398.89K | -67.91K |
| EBITDA | 817.00K | 366.89K |
| Interest Expense | 8.47K | 3.56K |
| Pretax Income | 591.83K | 126.46K |
| Tax Provision | 46.95K | 51.80K |
| Net Income | 544.88K | 74.66K |
| Diluted EPS | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2023 | Nov 2024 |
|---|---|---|
| Total Assets | 3.42M | 3.11M |
| Current Assets | 1.90M | 1.81M |
| Cash & Equivalents | 240.38K | 512.45K |
| Inventory | 473.22K | 368.76K |
| Receivables | 349.68K | 420.39K |
| Total Liabilities | 1.11M | 767.89K |
| Current Liabilities | 863.86K | 662.60K |
| Long Term Debt | - | - |
| Total Debt | 510.73K | 233.26K |
| Total Equity | 2.31M | 2.34M |
| Shares Outstanding | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Nov 2023 | Nov 2024 |
|---|---|---|
| Operating Cash Flow | -977.79K | 589.72K |
| Investing Cash Flow | -70.31K | -26.79K |
| Financing Cash Flow | 18.78K | -269.39K |
| Capital Expenditure | -70.31K | -26.79K |
| Free Cash Flow | -1.05M | 562.94K |
| Net Change in Cash | -1.03M | 293.55K |
Ratios (Annual)
Figures in %.
| Metric | Nov 2023 | Nov 2024 |
|---|---|---|
| Gross Margin % | 86.7% | 72.4% |
| Operating Margin % | 11.6% | -2.5% |
| Net Margin % | 15.9% | 2.7% |
| ROE % | 23.6% | 3.2% |
| ROCE % | 15.6% | -2.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIOT
Instinct Bio (BIOT) says Jakarta clinic build is progressing - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPOUFhUEpYZ1QtNldrT2NXWmlDZ2dkcHdsc09qVlR1NGpoeU1LTjFmMTVzZkNUQjVsbTNPS1BzaHVpN2lVZ2t6NDdGTEE4REZ3WVJ5bGI1Sk5ETnFXT21vdlBteXNTX3ZSaVhTOEtxeThaNVJnNWZhV09VbTh0S0d5VTdEME1mSERXMU5kRG…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBDT0NQVmVpNk9HWERMR0xEUDZoZkdac21zSGJFUWJfZE5rcVU1RUY4MDZ1clR3ZTg4OFNZbkRYVnVtZDVudi1mX1ROUGk2UkNt?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Instinct Bio Stock Slides After Hours: Here's What is Going on With BIOT - Benzinga
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOaFl5WG43Q0s1WWRHamVYa0xEZThNZEk2am1DQzM1Y1ZHX0VIbk40NUhzMmNrZnk2czY4UFdkTThtZTNURGZ1eUhPWWY1Qzl4dldPUEtCS256bDJNR0JrU2dNRkJUR3ZkeWE1SXdMRWFIRVZqaHY1bVhkVDVDVzg3c1hpakJ4cmZaNnlzWG…
BIOT - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5XMlF2WE14MDA5ZlZRc0kyOGIzcmNZclI5c2RrbUJEVWpIR2FGWGVhcWh5blg4aFRVTjM3WV9McG1qY3lLZGc?oc=5" target="_blank">BIOT</a> <font color="#6f6f6f">Finviz</font>…
A planned Jakarta clinic has preliminary membership prices up to $3,000 a month. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPalVFNkNzeVBPNlNUa2VuenRwcVlkX0VvODZINFlYN193M1NMVFRiY0xoZklzalpoMXNxMUFMd3JER01WdEk0clRHRWtDWTJfdzJkXzZrQUZ6R1dTRDRJYUVmZnVGaUlhYTgyNWZwZGZKRE0wSmxRMXZycE1GSThqXy1CSUZka1lnV2c2d0…
Market Movers | Winners: CNET, OPK, ITRI | Losers: YYAI, BIOT, SPWR - Trefis
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQUU1YZUtKNy12MkdDenVBelY1aFBvYk53LWdNVW9KNGhNblNjVTV5MFNoQjFJZWNRM3RPT2xsa1lDaE5uOUluV0tXM0VZbUJNVHhObFBsZkEzVFBremxVWUhrZDdYdUZyTlRkV2RmOFlWWXd0dHplSVIwMnFFMEVoRUV3Qlh3NFJ3d1dhb1…
BIOT — Frequently Asked Questions
What is the current share price of Instinct Bio Technical Company Holdings Inc. (BIOT)?
As of 2026-09-19 21:16 PDT, Instinct Bio Technical Company Holdings Inc. (BIOT) trades at $0.39 on NasdaqGM. Its 52-week range is $0.37 to $15.50.
What is the market capitalisation of BIOT?
Instinct Bio Technical Company Holdings Inc. (BIOT) has a market capitalisation of $11.23M on NasdaqGM.
What is the P/E ratio of BIOT?
BIOT trades at a trailing price-to-earnings (P/E) ratio of -39.00. The industry average P/E is 18.56.
What is the return on equity (ROE) of BIOT?
BIOT has a return on equity (ROE) of 3.19%. Its return on capital employed (ROCE) is 5.32%.
Is BIOT a good stock to buy?
This page provides a data-driven analysis of Instinct Bio Technical Company Holdings Inc. (BIOT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.